<?xml version='1.0' encoding='utf-8'?>
<document id="14628297"><sentence text="Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19."><entity charOffset="30-39" id="DDI-PubMed.14628297.s1.e0" text="methadone" /></sentence><sentence text="Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP"><entity charOffset="0-9" id="DDI-PubMed.14628297.s2.e0" text="Methadone" /><entity charOffset="31-37" id="DDI-PubMed.14628297.s2.e1" text="opioid" /><pair ddi="false" e1="DDI-PubMed.14628297.s2.e0" e2="DDI-PubMed.14628297.s2.e0" /><pair ddi="false" e1="DDI-PubMed.14628297.s2.e0" e2="DDI-PubMed.14628297.s2.e1" /></sentence><sentence text=" Methadone is a chiral drug administered as the racemic mixture of (R)-(-)- and (S)-(+)-methadone, but (R)-methadone is the active isomer"><entity charOffset="1-10" id="DDI-PubMed.14628297.s3.e0" text="Methadone" /><entity charOffset="103-116" id="DDI-PubMed.14628297.s3.e1" text="(R)-methadone" /><pair ddi="false" e1="DDI-PubMed.14628297.s3.e0" e2="DDI-PubMed.14628297.s3.e0" /><pair ddi="false" e1="DDI-PubMed.14628297.s3.e0" e2="DDI-PubMed.14628297.s3.e1" /></sentence><sentence text=" The cytochrome P450 (CYP) isoform involved in methadone's metabolism is thought to be CYP3A4, but human drug-drug interaction studies are not consistent with this" /><sentence text=" The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively"><entity charOffset="128-177" id="DDI-PubMed.14628297.s5.e0" text="2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine" /><entity charOffset="179-183" id="DDI-PubMed.14628297.s5.e1" text="EDDP" /><entity charOffset="190-207" id="DDI-PubMed.14628297.s5.e2" text="racemic methadone" /><entity charOffset="273-282" id="DDI-PubMed.14628297.s5.e3" text="methadone" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e0" e2="DDI-PubMed.14628297.s5.e0" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e0" e2="DDI-PubMed.14628297.s5.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e0" e2="DDI-PubMed.14628297.s5.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e0" e2="DDI-PubMed.14628297.s5.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e1" e2="DDI-PubMed.14628297.s5.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e1" e2="DDI-PubMed.14628297.s5.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e1" e2="DDI-PubMed.14628297.s5.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e2" e2="DDI-PubMed.14628297.s5.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s5.e2" e2="DDI-PubMed.14628297.s5.e3" /></sentence><sentence text=" Only CYP2B6, 2C19, and 3A4 generated measurable EDDP from 1 microg/ml of racemic methadone"><entity charOffset="74-91" id="DDI-PubMed.14628297.s6.e0" text="racemic methadone" /><entity charOffset="49-65" id="DDI-PubMed.14628297.s6.e1" text="EDDP" /><pair ddi="false" e1="DDI-PubMed.14628297.s6.e1" e2="DDI-PubMed.14628297.s6.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s6.e1" e2="DDI-PubMed.14628297.s6.e0" /></sentence><sentence text=" The hierarchy of EDDP generation was CYP2B6 &gt; CYP2C19 &gt;/= CYP3A4"><entity charOffset="18-21" id="DDI-PubMed.14628297.s7.e0" text="EDDP" /></sentence><sentence text=" At 10 microg/ml of methadone, CYP2C9 and CYP2D6 also generated EDDP, but in at least 10-fold lower quantities than CYP2B6"><entity charOffset="20-29" id="DDI-PubMed.14628297.s8.e0" text="methadone" /><entity charOffset="31-37" id="DDI-PubMed.14628297.s8.e1" text="CYP2C9" /><entity charOffset="64-69" id="DDI-PubMed.14628297.s8.e2" text="EDDP" /><pair ddi="false" e1="DDI-PubMed.14628297.s8.e0" e2="DDI-PubMed.14628297.s8.e0" /><pair ddi="false" e1="DDI-PubMed.14628297.s8.e0" e2="DDI-PubMed.14628297.s8.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s8.e0" e2="DDI-PubMed.14628297.s8.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s8.e1" e2="DDI-PubMed.14628297.s8.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s8.e1" e2="DDI-PubMed.14628297.s8.e2" /></sentence><sentence text=" Michaelis-Menten kinetic data demonstrated that CYP2B6 had the highest V(max) (44 ng/min/10pmol) and the lowest K(m) (12" /><sentence text="6 microg/ml) for EDDP formation of all the CYP isoforms"><entity charOffset="17-20" id="DDI-PubMed.14628297.s10.e0" text="EDDP" /></sentence><sentence text=" In human liver microsomes with high and low CYP2B6 expression but equivalent CYP3A4 expression, high CYP2B6 expression microsomes generated twice the amount of EDDP from 10 microg/ml of methadone than low CYP2B6 expression microsomes"><entity charOffset="187-196" id="DDI-PubMed.14628297.s11.e0" text="methadone" /><entity charOffset="161-169" id="DDI-PubMed.14628297.s11.e1" text="EDDP" /><pair ddi="false" e1="DDI-PubMed.14628297.s11.e1" e2="DDI-PubMed.14628297.s11.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s11.e1" e2="DDI-PubMed.14628297.s11.e0" /></sentence><sentence text=" When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference"><entity charOffset="36-53" id="DDI-PubMed.14628297.s12.e0" text="racemic methadone" /><entity charOffset="117-126" id="DDI-PubMed.14628297.s12.e1" text="methadone" /><entity charOffset="168-181" id="DDI-PubMed.14628297.s12.e2" text="(S)-methadone" /><entity charOffset="218-231" id="DDI-PubMed.14628297.s12.e3" text="(R)-methadone" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e0" e2="DDI-PubMed.14628297.s12.e0" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e0" e2="DDI-PubMed.14628297.s12.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e0" e2="DDI-PubMed.14628297.s12.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e0" e2="DDI-PubMed.14628297.s12.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e1" e2="DDI-PubMed.14628297.s12.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e1" e2="DDI-PubMed.14628297.s12.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e1" e2="DDI-PubMed.14628297.s12.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e2" e2="DDI-PubMed.14628297.s12.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s12.e2" e2="DDI-PubMed.14628297.s12.e3" /></sentence><sentence text=" These data suggest that multiple CYPs metabolized methadone but CYP2B6 had the highest V(max)/K(m)"><entity charOffset="51-60" id="DDI-PubMed.14628297.s13.e0" text="methadone" /></sentence><sentence text=" In addition, only CYP2B6 and 2C19 showed stereoselective metabolism" /><sentence text=" Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics"><entity charOffset="66-75" id="DDI-PubMed.14628297.s15.e0" text="methadone" /><entity charOffset="129-139" id="DDI-PubMed.14628297.s15.e1" text="nevirapine" /><entity charOffset="144-153" id="DDI-PubMed.14628297.s15.e2" text="efavirenz" /><entity charOffset="166-175" id="DDI-PubMed.14628297.s15.e3" text="methadone" /><entity charOffset="213-222" id="DDI-PubMed.14628297.s15.e4" text="rifabutin" /><entity charOffset="240-249" id="DDI-PubMed.14628297.s15.e5" text="methadone" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e0" e2="DDI-PubMed.14628297.s15.e0" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e0" e2="DDI-PubMed.14628297.s15.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e0" e2="DDI-PubMed.14628297.s15.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e0" e2="DDI-PubMed.14628297.s15.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e0" e2="DDI-PubMed.14628297.s15.e4" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e0" e2="DDI-PubMed.14628297.s15.e5" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e1" e2="DDI-PubMed.14628297.s15.e1" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e1" e2="DDI-PubMed.14628297.s15.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e1" e2="DDI-PubMed.14628297.s15.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e1" e2="DDI-PubMed.14628297.s15.e4" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e1" e2="DDI-PubMed.14628297.s15.e5" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e2" e2="DDI-PubMed.14628297.s15.e2" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e2" e2="DDI-PubMed.14628297.s15.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e2" e2="DDI-PubMed.14628297.s15.e4" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e2" e2="DDI-PubMed.14628297.s15.e5" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e3" e2="DDI-PubMed.14628297.s15.e3" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e3" e2="DDI-PubMed.14628297.s15.e4" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e3" e2="DDI-PubMed.14628297.s15.e5" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e4" e2="DDI-PubMed.14628297.s15.e4" /><pair ddi="false" e1="DDI-PubMed.14628297.s15.e4" e2="DDI-PubMed.14628297.s15.e5" /></sentence><sentence text="" /></document>